Epoch Investment Partners Inc. lifted its position in United Therapeutics Co. (NASDAQ:UTHR – Free Report) by 0.1% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 213,498 shares of the biotechnology company’s stock after buying an additional 319 shares during the period. Epoch Investment Partners Inc. owned about 0.48% of United Therapeutics worth $49,045,000 as of its most recent SEC filing.
Several other hedge funds have also added to or reduced their stakes in UTHR. Norges Bank acquired a new position in United Therapeutics in the 4th quarter worth $100,519,000. Nordea Investment Management AB boosted its position in United Therapeutics by 677.6% during the 1st quarter. Nordea Investment Management AB now owns 300,920 shares of the biotechnology company’s stock worth $72,422,000 after acquiring an additional 262,222 shares during the last quarter. Avidity Partners Management LP acquired a new stake in shares of United Therapeutics in the fourth quarter valued at approximately $52,158,000. Canada Pension Plan Investment Board lifted its position in shares of United Therapeutics by 567.2% in the first quarter. Canada Pension Plan Investment Board now owns 180,800 shares of the biotechnology company’s stock worth $41,533,000 after purchasing an additional 153,700 shares in the last quarter. Finally, LSV Asset Management grew its position in United Therapeutics by 40.3% in the first quarter. LSV Asset Management now owns 529,519 shares of the biotechnology company’s stock valued at $121,641,000 after purchasing an additional 152,151 shares in the last quarter. Institutional investors and hedge funds own 94.08% of the company’s stock.
United Therapeutics Price Performance
Shares of UTHR traded up $1.85 during trading hours on Friday, hitting $338.22. 290,258 shares of the company were exchanged, compared to its average volume of 439,807. The company has a quick ratio of 3.64, a current ratio of 3.77 and a debt-to-equity ratio of 0.04. United Therapeutics Co. has a fifty-two week low of $208.62 and a fifty-two week high of $343.98. The company has a market cap of $15.00 billion, a price-to-earnings ratio of 15.99, a P/E/G ratio of 1.48 and a beta of 0.55. The firm’s fifty day moving average is $303.01 and its 200 day moving average is $257.47.
Insider Activity at United Therapeutics
In other United Therapeutics news, CEO Martine A. Rothblatt sold 3,600 shares of the firm’s stock in a transaction on Thursday, May 2nd. The stock was sold at an average price of $258.09, for a total value of $929,124.00. Following the sale, the chief executive officer now owns 130 shares of the company’s stock, valued at approximately $33,551.70. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. In related news, CEO Martine A. Rothblatt sold 3,600 shares of United Therapeutics stock in a transaction that occurred on Thursday, May 2nd. The shares were sold at an average price of $258.09, for a total transaction of $929,124.00. Following the sale, the chief executive officer now directly owns 130 shares of the company’s stock, valued at approximately $33,551.70. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Nilda Mesa sold 266 shares of the stock in a transaction that occurred on Tuesday, June 25th. The shares were sold at an average price of $318.58, for a total transaction of $84,742.28. Following the completion of the transaction, the director now directly owns 5,107 shares of the company’s stock, valued at approximately $1,626,988.06. The disclosure for this sale can be found here. Insiders have sold 100,884 shares of company stock valued at $29,622,803 over the last three months. 12.50% of the stock is owned by insiders.
Analyst Ratings Changes
UTHR has been the topic of several analyst reports. JPMorgan Chase & Co. boosted their price target on shares of United Therapeutics from $280.00 to $300.00 and gave the stock an “overweight” rating in a research report on Tuesday, May 21st. HC Wainwright upped their target price on United Therapeutics from $300.00 to $400.00 and gave the stock a “buy” rating in a report on Thursday. Morgan Stanley downgraded United Therapeutics from an “overweight” rating to an “equal weight” rating and raised their price target for the company from $310.00 to $321.00 in a research note on Thursday, July 11th. UBS Group boosted their price target on United Therapeutics from $300.00 to $370.00 and gave the stock a “buy” rating in a research report on Monday, July 8th. Finally, TD Cowen raised their target price on shares of United Therapeutics from $270.00 to $350.00 and gave the company a “buy” rating in a research note on Thursday, July 11th. Two equities research analysts have rated the stock with a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $330.64.
Read Our Latest Analysis on UTHR
United Therapeutics Company Profile
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.
Featured Articles
- Five stocks we like better than United Therapeutics
- How Investors Can Find the Best Cheap Dividend Stocks
- Is Crypto Cool Again? What Stocks You Should Be Watching
- The Role Economic Reports Play in a Successful Investment Strategy
- Why Call Options Volume for These 2 Stocks Spiked Together
- How to Know Which Cryptocurrency to Buy: A Guide for Investors
- MarketBeat Week in Review – 7/22 – 7/26
Want to see what other hedge funds are holding UTHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for United Therapeutics Co. (NASDAQ:UTHR – Free Report).
Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.